Full-Time

Machine Learning Engineer

AI Studio

Updated on 8/23/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's, Master's

Category
AI & Machine Learning (1)
Required Skills
LLM
Scikit-learn
Kubernetes
MLOps
Python
Airflow
Incident Response
GitHub Actions
Regression
TensorFlow
Neural Networks
PyTorch
Xgboost
Apache Spark
SQL
Machine Learning
MLflow
Infrastructure as Code (IaC)
Docker
RAG
Version Control
AWS
LangGraph
Observability
REST APIs
LangChain
DevOps
Computer Vision
Databricks
Data Analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • Bachelor's or Master's degree and 5 to 9 years of Computer Science, Information Technology, or related field experience.
  • Demonstrated ownership of at least one production software, data, machine learning, Generative AI, or automation component.
  • Strong hands-on proficiency in Python and SQL, with sound software-engineering and testing practices.
  • Strong capability in at least one of classical machine learning, Generative AI/retrieval-augmented generation/agents, or MLOps/platform engineering, with working knowledge of adjacent areas.
  • Production software and AI/ML system design using Python and SQL modules, APIs, background jobs, event flows, testing, performance, observability, source control, and maintainable failure semantics.
  • Statistics, modeling, and experimentation including exploratory data analysis, feature engineering, classification, regression, clustering, ensembles, cross-validation, leakage prevention, calibration, uncertainty, and decision-aware error analysis.
  • Generative AI, retrieval-augmented generation, knowledge, and agent capabilities including prompt and context management, structured output, chunking, embeddings, hybrid retrieval, reranking, citations, access-aware retrieval, tool schemas, and human approval.
  • Data, knowledge, and cloud-scale systems experience with batch and event-driven pipelines, contracts, lineage, provenance, relational/document/graph/vector stores, APIs, containers, Spark or Databricks, and cloud-native services.
  • AI evaluation and MLOps/LLMOps experience with representative measures, versioning, CI/CD, release gates, quality and drift monitoring, incidents, rollback, runbooks, component support, and lifecycle traceability.
  • Responsible and regulated delivery practices including least privilege, privacy, prompt-injection safeguards, bias and robustness checks, intended-use documentation, human oversight, auditability, and GxP evidence.
Responsibilities
  • Define component boundaries, intended use, acceptance criteria, non-functional requirements, decision consequences, support expectations, and technical estimates with product and architecture partners.
  • Design and implement maintainable Python, SQL, API, data, model, retrieval, agent-tool, and workflow components with clear contracts, configuration, testing, error handling, and documentation.
  • Apply exploratory data analysis, feature engineering, supervised or unsupervised methods, baselines, cross-validation, leakage prevention, calibration, subgroup analysis, threshold analysis, explainability, and error analysis where relevant.
  • Build Generative AI, natural language processing, retrieval-augmented generation, and bounded-agent components using structured output, embeddings, hybrid search, reranking, provenance, citations, permissions, approvals, retries, and recoverable failure behavior.
  • Engineer batch or event-driven data, document, feature, embedding, label, and evaluation pipelines with schema validation, lineage, provenance, access control, and consistency checks.
  • Define representative evaluation for model quality, uncertainty, retrieval, grounding, citations, task success, tool correctness, safety, latency, cost, and user impact.
  • Release and support components using cloud services, containers, CI/CD, versioning, monitoring, rollback, incident response, and runbooks; lead diagnosis of moderately complex failures.
  • Apply security, privacy, Responsible AI, validation, auditability, human oversight, and applicable GxP controls; contribute reusable assets and guide Associate engineers on familiar work.
Desired Qualifications
  • Experience with PyTorch, TensorFlow, Hugging Face, scikit-learn, XGBoost, PyMC, computer vision, natural language processing, graph neural networks, causal inference, or uncertainty estimation.
  • Experience with LangChain, LangGraph, LlamaIndex, Semantic Kernel, AutoGen, CrewAI, hybrid retrieval, knowledge graphs, graph retrieval-augmented generation, or evidence verification.
  • Experience with AWS, Bedrock or SageMaker, Databricks, Spark, Kubernetes, infrastructure as code, MLflow, Airflow, Kubeflow, or GitHub Actions.
  • Familiarity with MCP-style integration, agent tracing, adversarial testing, durable workflows, permissions, human review, business intelligence, or process automation.
  • Experience in healthcare, life sciences, GxP, validated systems, or another regulated or high-impact environment.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $10.1 billion, up 10%, and guidance rose to $39.4 billion.
  • Repatha, Evenity, and Uplizna surged 37%, 38%, and 90% in Q2 2026.
  • Amgen presented Repatha VESALIUS-CV data for ESC August 2026, expanding cardiovascular adoption.

What critics are saying

  • FDA proposed withdrawing Tavneos on April 27, 2026; EMA echoed revocation on June 26.
  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy franchise.
  • Harbour BioMed won a June 2026 willful patent verdict; MariTide failure would crush growth.

What makes Amgen unique

  • Amgen’s portfolio spans cardiovascular, bone, immunology, oncology, and biosimilars.
  • MariTide targets monthly or less frequent obesity dosing, unlike weekly GLP-1 rivals.
  • Amgen runs seven research labs plus Hyderabad’s 2027 science and innovation center.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.